BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1214 related articles for article (PubMed ID: 12195419)

  • 1. [Case report: reversible acute renal failure following therapy with both ketorolac (non-selective non-steroidal anti-inflammatory drug NSAID) and celecoxib (COX-2 selective) in the same patient].
    Galli G; Panzetta G
    G Ital Nefrol; 2002; 19(2):199-203. PubMed ID: 12195419
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Do non-steroidal anti-inflammatory drugs and COX-2 selective inhibitors have different renal effects?
    Giovanni G; Giovanni P
    J Nephrol; 2002; 15(5):480-8. PubMed ID: 12455713
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dual acting anti-inflammatory drugs: a reappraisal.
    Bertolini A; Ottani A; Sandrini M
    Pharmacol Res; 2001 Dec; 44(6):437-50. PubMed ID: 11735348
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differential inhibition of fracture healing by non-selective and cyclooxygenase-2 selective non-steroidal anti-inflammatory drugs.
    Gerstenfeld LC; Thiede M; Seibert K; Mielke C; Phippard D; Svagr B; Cullinane D; Einhorn TA
    J Orthop Res; 2003 Jul; 21(4):670-5. PubMed ID: 12798067
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Coxibs: cyclooxygenase-2 inhibitors].
    Turnheim K
    Wien Klin Wochenschr; 2001 Aug; 113(15-16):558-65. PubMed ID: 11571832
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Celecoxib, a highly selective COX-2 inhibitor, is safe in aspirin-induced asthma patients.
    Martín-García C; Hinojosa M; Berges P; Camacho E; García-Rodriguez R; Alfaya T
    J Investig Allergol Clin Immunol; 2003; 13(1):20-5. PubMed ID: 12861847
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Renal tolerance of selective inhibitors of cyclooxygenase type 2].
    Deray G
    Presse Med; 2001 Oct; 30(30):1507-12. PubMed ID: 11712212
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A comparison of renal-related adverse drug reactions between rofecoxib and celecoxib, based on the World Health Organization/Uppsala Monitoring Centre safety database.
    Zhao SZ; Reynolds MW; Lejkowith J; Whelton A; Arellano FM
    Clin Ther; 2001 Sep; 23(9):1478-91. PubMed ID: 11589261
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New NSAIDs and gastroduodenal damage.
    Folco GC
    Ital J Gastroenterol; 1996 Dec; 28 Suppl 4():28-9. PubMed ID: 9032579
    [TBL] [Abstract][Full Text] [Related]  

  • 10. NSAID-induced gastric damage in rats: requirement for inhibition of both cyclooxygenase 1 and 2.
    Wallace JL; McKnight W; Reuter BK; Vergnolle N
    Gastroenterology; 2000 Sep; 119(3):706-14. PubMed ID: 10982765
    [TBL] [Abstract][Full Text] [Related]  

  • 11. COX-2 selective non-steroidal anti-inflammatory drugs and cardiovascular disease.
    Ray WA; MacDonald TM; Solomon DH; Graham DJ; Avorn J
    Pharmacoepidemiol Drug Saf; 2003; 12(1):67-70. PubMed ID: 12616850
    [No Abstract]   [Full Text] [Related]  

  • 12. Comparison of the baseline cardiovascular risk profile among hypertensive patients prescribed COX-2-specific inhibitors or nonspecific NSAIDs: data from real-life practice.
    Zhao SZ; Burke TA; Whelton A; von Allmen H; Henderson SC
    Am J Manag Care; 2002 Oct; 8(15 Suppl):S392-400. PubMed ID: 12416789
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nonsteroidal anti-inflammatory drugs increase expression of inducible COX-2 isoform of cyclooxygenase in spinal cord of rats with adjuvant induced inflammation.
    Hsueh SF; Lu CY; Chao CS; Tan PH; Huang YW; Hsieh SW; Hsiao HT; Chung NC; Lin SH; Huang PL; Lyu PC; Yang LC
    Brain Res Mol Brain Res; 2004 Jun; 125(1-2):113-9. PubMed ID: 15193428
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost of heart failure among hypertensive users of nonspecific NSAIDs and COX-2-specific inhibitors.
    Zhao SZ; Burke TA; Whelton A; von Allmen H; Henderson SC
    Am J Manag Care; 2002 Oct; 8(15 Suppl):S414-27. PubMed ID: 12416791
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Update on clinical developments with celecoxib, a new specific COX-2 inhibitor: what can we expect?
    Geis GS
    Scand J Rheumatol Suppl; 1999; 109():31-7. PubMed ID: 10422544
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Wound collagen deposition in rats: effects of an NO-NSAID and a selective COX-2 inhibitor.
    Muscará MN; McKnight W; Asfaha S; Wallace JL
    Br J Pharmacol; 2000 Feb; 129(4):681-6. PubMed ID: 10683192
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of angiotensin II activity enhanced the antitumor effect of cyclooxygenase-2 inhibitors via insulin-like growth factor I receptor pathway.
    Yasumaru M; Tsuji S; Tsujii M; Irie T; Komori M; Kimura A; Nishida T; Kakiuchi Y; Kawai N; Murata H; Horimoto M; Sasaki Y; Hayashi N; Kawano S; Hori M
    Cancer Res; 2003 Oct; 63(20):6726-34. PubMed ID: 14583467
    [TBL] [Abstract][Full Text] [Related]  

  • 18. COX-1 and COX-2 inhibitors.
    Hawkey CJ
    Best Pract Res Clin Gastroenterol; 2001 Oct; 15(5):801-20. PubMed ID: 11566042
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [COX-2 inhibitor non-steroidal anti-inflammatory drugs, myth or reality?].
    Peretz A
    Rev Med Brux; 2001 Sep; 22(4):A377-80. PubMed ID: 11680204
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nephrotic syndrome and interstitial nephritis associated with celecoxib.
    Alper AB; Meleg-Smith S; Krane NK
    Am J Kidney Dis; 2002 Nov; 40(5):1086-90. PubMed ID: 12407655
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 61.